Neurogene was founded to bring life-changing medicines to patients and families affected by rare neurological disorders. We partner with leading academic researchers, patient advocacy organizations and caregivers to bring to patients therapies that address the underlying genetic cause of a broad spectrum of neurological diseases where no effective treatment options exist today. Our lead programs use AAV-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene. Neurogene is also investing in novel technology to develop treatments for diseases not well served by gene therapy.

Biotechnology

Neurogene

Neurogene's headquarters in New York, NY, United States

Rachel McMinn

Kimberly Trant, RN, MBA

Ellery Mangas

Efsevia (Effie) Albanis

Craig Hebel

Bridget M.

Andrew Mulberg

Christine Mikail

Ricardo Jimenez

Stuart Cobb

Arvind Sreedharan

Description

People (10)

Rachel McMinn

Christine Mikail

Effie Albanis

James Pellecchia, CPA

Cynthia F.

Justine Mulhall Hickey

Efsevia (Effie) Albanis

Nanette Cabaccang

Caryn Blumenfeld

Hiram Valencia

Jobs